TABLE 1.
Eleven (poly)peptides identified in nasal secretions by Western analysis, microsequencing, and/or mass spectrometry
| Protein | Molecular size (kDa) | Concn (μg/ml)a | Method of detectionb |
|---|---|---|---|
| Lysozyme | 14.7 | 250–500 | a, b, c |
| Lactoferrin | 78 | 80–200 | a |
| SLPI | 11.7 | 10–80 | a, b, c |
| β-Microseminoprotein | 10.8 | ND | b, c |
| sPLA2 | 14.1 | ND | d |
| Statherin | 5.2 | ND | b, c |
| Light-chain IgG | ∼28 | ND | b |
| Albumin | ∼6 (fragment) | ND | b |
| Albumin | ∼30 (fragment) | ND | b |
| Albumin | ∼31 (fragment) | ND | b |
| HBD-1c | 3.9 | ND | a |
| HBD-2c | 4.3 | 0.3–4 | a |
| HNP-1 | 3.4 | ND | b |
a
Concentration was determined from five samples by using semi quantitative Western analysis, with each sample containing lysozyme, lactoferrin, and SLPI. Note that three of five donor samples contained measurable amounts (>0.3 μg/ml) of HBD-2. ND, not determined.
b
a, Western analysis; b, microsequencing by N-terminal Edman degradation; c, mass spectroscopy; d, PLA2 activity determined by using radiolabeled E. coli ML-35p substrate as described previously (31).
c
Some β-defensin comigrated with higher-molecular-weight proteins.